Compare EPM & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EPM | MOLN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.2M | 158.9M |
| IPO Year | 1996 | 2021 |
| Metric | EPM | MOLN |
|---|---|---|
| Price | $4.47 | $4.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.93 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 413.9K | 3.6K |
| Earning Date | 05-12-2026 | 03-12-2026 |
| Dividend Yield | ★ 10.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $43,229,621.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $318.52 |
| P/E Ratio | $90.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $3.36 |
| 52 Week High | $5.70 | $5.36 |
| Indicator | EPM | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 40.55 |
| Support Level | $4.38 | $4.04 |
| Resistance Level | $4.63 | $4.63 |
| Average True Range (ATR) | 0.15 | 0.27 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 16.67 | 17.37 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.